Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains
Xiande Huang Ziqi Cheng Yake Lv Weixuan Li Xiaoyu Liu Weijin Huang Chenyan Zhao a Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control (NIFDC),Beijing,Chinab Center of Vaccine Clinical Evaluation,Institute for Immunization Program,Shaanxi Provincial Centre for Disease Control and Prevention,Xi'an,Shaanxi Province,ChinaXiande Huang Ph.D.,with a focus on research in influenza virus vaccinology,has published over ten articles in journals such as Philosophical Transactions of the Royal Society B,Virus Research,Viruses,and Plant Disease,and has been granted one patent.Ziqi Cheng Ph.D.,primarily focuses on influenza virus vaccinology and mRNA vaccine research,has published an article as the first author in 《Translational Cancer》.Yake Lv born in November 1995. Master Degree,Attending physician. Shaanxi Provincial Center for Disease Control and Prevention Immunization Program (Vaccine Clinical Evaluation Center),mainly responsible for vaccine against infectious disease control,vaccine clinical research and other work. In the past 5 years,has published two papers as the first three authors and participated in two phase III and phase IV vaccine clinical trials.Weixuan Li born on April 8,1994,got master degree and intern researcher. As a employee of the Immunization Program Institute (Vaccine Clinical Evaluation Center) of Shaanxi Provincial Center for Disease Control and Prevention,mainly responsible for mumps epidemiology and laboratory related work,vaccine-related infectious diseases bacteria-related laboratory,vaccine clinical research and other work. In the past two years,has published two papers as the first three authors and participated in two phase III and phase IV vaccine clinical trials.Xiaoyu Liu Master student,Deputy chief clinician. Deputy Director ofImmunization Program Institute (Vaccine Clinical Evaluation Center) of Shaanxi Provincial Center for Disease Control and Prevention,mainlyresponsible for vaccine control of infectious diseases,vaccine clinicalresearch and other work. Member of Vaccine Clinical Research Branch of China Vaccine Industry Association,Member of Japanese encephalic Prevention and Control Branch of China Vaccine Industry Association,member of Vaccine and Health Branch of China Geriatric Health Association,Standing member of Clinical Research and Medical Ethics Special Committee of Shaanxi International Medical Exchange Promotion Association. In the past 5 years,she has published 14 papers,applied for and participated in 4 projects at the Ministry of Science and Technology,provincial and departmental levels,and undertook 17 phase I,II,III and IV vaccine clinical trials.Weijin Huang M.D.,serves as the director of the Division of HIV/AIDS and Sex-transmitted Virus Vaccines at NIFDC. Research focuses on the quality assessment and study of products related to HIV,HPV,HEV,influenza,and emerging infectious disease pathogens such as COVID-19. As principal investigator,he has led numerous projects,including those funded by the National Natural Science Foundation,the National Key R&D Program,and the Gates Foundation's COVID-19 initiatives. Published over 100 SCI papers as the first or corresponding author and holds 15 granted patents.Chenyan Zhao Ph.D.,is a research fellow and the principal of Influenza and HIV Vaccine Products at the National Institutes for Food and Drug Control in China. Research focuses on the quality assessment of products related to influenza virus,HIV,and hepatitis E virus,as well as the development of pseudovirus platforms for highly pathogenic infectious diseases. Over the past 5 years,Dr. Zhao has led three national-level projects,including 13th Five-Year National Major Projects and the National Key R&D Program; contributed to five provincial and ministerial-level projects. Published over 30 SCI papers as the first or corresponding author,holds four patents. Co-authored three books in both Chinese and English.
DOI: https://doi.org/10.1080/21645515.2024.2380111
2024-08-31
Human Vaccines & Immunotherapeutics
Abstract:Seasonal influenza is a severe disease that significantly impacts public health, causing millions of infections and hundreds of thousands of deaths each year. Seasonal influenza viruses, particularly the H3N2 subtype, exhibit high antigenic variability, often leading to mismatch between vaccine strains and circulating strains. Therefore, rapidly assessing the alignment between existing seasonal influenza vaccine and circulating strains is crucial for enhancing vaccine efficacy. This study, based on a pseudovirus platform, evaluated the match between current influenza H3N2 vaccine strains and circulating strains through cross-neutralization assays using clinical human immune sera against globally circulating influenza virus strains. The research results show that although mutations are present in the circulating strains, the current H3N2 vaccine strain still imparting effective protection, providing a scientific basis for encouraging influenza vaccination. This research methodology can be sustainably applied for the neutralization potency assessment of subsequent circulating strains, establishing a persistent methodological framework.
immunology,biotechnology & applied microbiology